Triple
T5689095
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CLARITY AD |
E125383
|
entity |
| Predicate | coDevelopment |
P6901
|
FINISHED |
| Object | Eisai and Biogen |
E132619
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Eisai and Biogen | Statement: [CLARITY AD, coDevelopment, Eisai and Biogen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Eisai and Biogen Context triple: [CLARITY AD, coDevelopment, Eisai and Biogen]
-
A.
Eisai and Biogen
chosen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
D.
Eisai
Eisai was a Japanese Buddhist monk of the Kamakura period best known for introducing Rinzai Zen and promoting tea culture in Japan.
-
E.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: coDevelopment Context triple: [CLARITY AD, coDevelopment, Eisai and Biogen]
-
A.
development
Indicates a process or relationship in which something grows, advances, or becomes more complex or mature over time.
-
B.
developedWithin
Indicates that something was created, produced, or brought into existence inside a specified context, boundary, or time frame.
-
C.
alsoDevelopedIn
Indicates that something was additionally developed in another context, location, or environment beyond the primary one already specified.
-
D.
coDeveloperOf
chosen
Indicates that two or more entities jointly developed or collaborated in creating the same project, product, or work.
-
E.
canDevelop
Indicates that one entity has the ability or capacity to develop, create, or build another entity.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0082bb19c8190823a4facd3cba79b |
completed | March 22, 2026, 3:18 p.m. |
| NER | Named-entity recognition | batch_69c029014588819094a2a0f6f9b66bab |
completed | March 22, 2026, 5:38 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c07dd1758c8190ad92f250e5927c0b |
completed | March 22, 2026, 11:40 p.m. |
| PD | Predicate disambiguation | batch_69c021c0e0408190ab6c3cd3f907e80f |
completed | March 22, 2026, 5:07 p.m. |
Created at: March 22, 2026, 3:44 p.m.